In a statement, Mylan said the settlement did not imply any admission of wrongdoing. The makers of generic drugs pay rebates to the government of 13 percent of the average manufacturers’ price. EpiPen contains epinephrine, a drug that is available as a cheap generic, but Mylan has the exclusive right to sell the drug as part of a patented auto-injector. Mylan will take a $465 million charge in the third quarter to pay for the settlement, the company said. It also has announced plans to begin selling a generic version of the EpiPen at a lower list price.

Source: New York Times October 07, 2016 21:22 UTC